Pharmacometrics Talent Market Report 2026

What Current Hiring Activity Is Showing

Pharmacometrics continues to play an increasingly visible role across drug development, particularly as companies apply quantitative approaches to dose selection, clinical trial design, regulatory strategy, and model-informed drug development.

Across the Pharmacometrics positions we reviewed in 2026, several patterns stand out: population PK/PD and exposure-response remain foundational, regulatory responsibilities are common, and the scope of expertise expands considerably at more experienced levels.

Here is what we are seeing across the market. 

Experienced Pharmacometrics Talent Remains a Hiring Focus

Many of the opportunities we reviewed were positioned at the Associate Director, Director, Senior Director, or other experienced scientific levels.

At these levels, responsibilities extended beyond conducting analyses into areas such as quantitative strategy, cross-functional program leadership, regulatory support, and scientific oversight.

More junior Pharmacometrician opportunities remain in the market, but their scope tends to center more heavily on hands-on analysis and model development.

At more experienced levels, we also saw responsibilities involving dose optimization, clinical trial simulation, model-based meta-analysis, disease progression modeling, time-to-event analysis, PBPK, and QSP, depending on the program and development question.

The distinction is therefore not simply one of technical experience. The positions reviewed show a broader progression in scientific scope, strategic responsibility, and influence across development programs.

What Skills Are Appearing Most Often?

Population PK/PD

More than 80% of the roles reviewed referenced population PK, PK/PD modeling, or closely related pharmacometric analyses.

Applications ranged from hands-on model development to strategic oversight of analyses conducted internally or through CRO partners.

Exposure-Response

Roughly three-quarters of the roles reviewed included exposure-response analysis or its application within development programs.

Common applications included:

• Dose selection and optimization
• Efficacy and safety assessment
• Clinical trial strategy
• Regulatory dose justification

Together, population PK/PD and exposure-response remain two of the clearest technical foundations across the Pharmacometrics positions we reviewed.

Regulatory Experience Is Closely Tied to Pharmacometrics Hiring

More than 80% of the roles reviewed included some form of regulatory responsibility.

The scope ranged from preparing modeling reports and Clinical Pharmacology sections to supporting or participating directly in Health Authority interactions.

Responsibilities included:

• Population PK and exposure-response reports
• Modeling and simulation analysis plans
• IND, NDA, BLA, and MAA support
• Health Authority responses and interactions
• Dose justification
• Labeling support

The depth naturally varied by seniority, but regulatory involvement was one of the most consistent characteristics across the market we reviewed.

MIDD Is Becoming Part of the Broader Development Strategy

Model-Informed Drug Development appeared frequently across the positions reviewed, generally in connection with specific development questions.

Common applications included:

Dose selection and optimization – determining appropriate doses and regimens.

Clinical trial design – informing study design, sampling, endpoints, and patient populations.

First-in-human development – applying translational and mechanistic approaches to early clinical strategy.

Exposure-response – evaluating relationships between exposure, efficacy, and safety.

Regulatory strategy – providing quantitative evidence for dose justification and regulatory submissions.

Rather than appearing as a separate discipline, MIDD was commonly embedded within the broader Pharmacometrics and Clinical Pharmacology strategy of development programs.

NONMEM and R Remain Core Tools

NONMEM and R were the two most frequently referenced tools across the positions reviewed.

Other platforms included:

Phoenix / Phoenix NLME • Monolix • MATLAB • Python • Simcyp • GastroPlus • Pirana • mrgsolve • Julia

The specific toolset varied according to the modeling approach and organization, but NONMEM and R remained the most consistent technical platforms across the roles reviewed.

The Modeling Toolkit Is Expanding

Beyond population PK/PD and exposure-response, the positions reviewed included a wider range of quantitative methodologies:

Clinical Trial Simulation • Disease Progression Modeling • Time-to-Event Analysis • Model-Based Meta-Analysis • PBPK • QSP • Mechanistic Modeling • Bayesian Methods • AI/ML

These were not universal requirements, nor do they appear to be replacing traditional Pharmacometrics.

Instead, they reflect the range of approaches that may be applied to different development questions.

For example, disease progression and time-to-event models can help characterize changes or clinical outcomes over time, while model-based meta-analysis can place emerging data within the context of existing evidence. PBPK and QSP can provide more mechanistic approaches when understanding physiology, drug disposition, biological pathways, or translational relationships becomes important.

AI/ML also appeared in several positions, although much less consistent than established pharmacometric methodologies.

Therapeutic Area and Modality Add Another Layer of Specialization

The positions reviewed supported a range of therapeutic areas, including:

Oncology • Neuroscience • Inflammation • Virology • Rare Disease • Endocrine Disease • Genetic Medicines

Alongside traditional small molecules and biologics, we also saw roles supporting:

Oligonucleotides • Antibody-Drug Conjugates • Radioligand Therapies • Cell Therapies

This adds another layer of specificity to the talent market.

Two scientists may have comparable population PK/PD or exposure-response expertise while bringing very different experience with a particular modality, therapeutic area, or stage of development.

What This Means for Pharmacometrics Hiring

The Pharmacometrics talent market in 2026 does not appear to be moving away from its traditional quantitative foundations.

Instead, the scope surrounding those foundations is expanding.

Population PK/PD and exposure-response remain central, while more experienced roles can add requirements around advanced modeling methodologies, regulatory experience, program strategy, therapeutic area or modality expertise, and scientific leadership.

For hiring teams, this creates an increasingly specific combination of capabilities to consider when evaluating experienced Pharmacometrics talent.

Looking Ahead

As model-informed approaches become more deeply embedded in drug development and newer modalities introduce different quantitative questions, Pharmacometrics remains an important talent market to follow.

The foundations of the discipline remain clear. What continues to evolve is the breadth of methodologies being applied and the context in which that expertise is needed.

At Hughes & Associates, we continuously follow these developments alongside hiring and talent movement across Pharmacometrics, Clinical Pharmacology, QSP, DMPK, Bioanalysis, and related quantitative and translational sciences functions.

Our focus is on understanding how these areas are evolving and what those changes may mean for the companies and professionals working within them.

If your organization is navigating a search, considering future workforce needs, or simply looking to compare notes on what we are seeing across the market, we would be glad to connect for a confidential conversation.

To learn more about Hughes & Associates and our specialized life sciences search capabilities, visit our website: https://www.haallc.com

For additional market insights, industry updates, and talent trends, follow Hughes & Associates on LinkedIn, Instagram, Facebook, X and Youtube.

Read More

Q2 2026 Biopharma Market Update: Capital Is Returning, but the Recovery Remains Selective

DMPK Talent Market Report 2026: What Hiring Leaders Should Know

Understanding the Clinical Pharmacology and Pharmacometrics Leadership Talent Pool